

CaRI-Heart® Coronary Inflammation and Risk Report Instructions for Use

18 June 2024

Intended Audience

This document is for use by healthcare professionals who will receive a CaRI-Heart Coronary Inflammation, Plaque, and Risk Report from Caristo Diagnostics.

Indications for use

- CaRI-Heart is a software device used to produce analysis results to assist Healthcare Professionals in patient management. It helps operators assess information about vascular-related inflammation, plaque and stenosis from computed tomography angiography images and calculates measures related to the risk of cardiac mortality due to coronary-related inflammation and other clinical risk factors.
- CaRI-Heart and its analysis results are indicated for use for all adult patients referred for CCTA imaging.
- CaRI-Heart is to be used by trained operators. CaRI-Heart analysis results are to be used by Healthcare Professionals.
- CaRI-Heart analysis results should be reviewed with other clinical information which may include, but is not limited to: the patient's original CT images, clinical history, symptoms, clinical risk factors, results of other diagnostic tests, and the clinical judgement of appropriately qualified Healthcare Professionals.

Imaging pre-requisites

- Patient should be between 30 - 80 years old.
- Images should be acquired using a CCTA protocol on a 64-slice scanner or above.
- Images should have a slice thickness of less than 1mm.
- Images should be acquired at peak energies of 70, 80, 90, 100, 110, 120, 140 kVp or on a photon counting scanner using a 140kVp tube voltage and a 67 keV virtual monoenergetic image with a QR44 Filter for reconstruction.
- Images should include the pulmonary artery bifurcation cranially and fully include the apex of the heart caudally.

A paper copy of this eIFU may be requested from the manufacturer at no additional cost. A paper copy will be provided within 7 days of request.

Device: CaRI-Heart 2.6
Reference: 1964
Copyright © 2024
Caristo Diagnostics Ltd




Manufacturer
Caristo Diagnostics Ltd.
New Barclay House
234 Botley Road
Oxford, OX2 0HP
United Kingdom



EC Representative
EMERGO Europe
Prinsessegracht 20
The Hague
2514 AP
The Netherlands

Description of CaRi-Heart Report Content

CaRi-Heart® Coronary Inflammation and Risk Reports provide information about plaque, coronary-related inflammation and the inflammation-associated risk of cardiac mortality.



The CaRi-Heart® Plaque, Coronary Inflammation and Risk Report provides the following measures:

- 1 **FAI-Score** The highest FAI-Score of vessels measured: a standardised modifiable measure of coronary inflammation reported per patient:
- 2 **CaRi-Heart Risk** a measure of the 8-year risk of cardiac mortality, taking into account coronary inflammation, atherosclerotic plaque, patient demographics and clinical risk factors
- 3 **FAI** reported per vessel: a modifiable measure of coronary inflammation (Fat Attenuation Index) Displayed with PFA images.

A paper copy of this eFU may be requested from the manufacturer at no additional cost. A paper copy will be provided within 7 days of request.


Device: CaRI-Heart 2.6
 Reference: 1964
 Copyright © 2024
 Caristo Diagnostics Ltd
 Rx Only UK CA CE
 0086 2797



Manufacturer
 Caristo Diagnostics Ltd.
 New Barclay House
 234 Botley Road
 Oxford, OX2 0HP
 United Kingdom




EC Representative
 EMERGO Europe
 Prinsessegracht 20
 The Hague
 2514 AP
 The Netherlands




- 1 **FAI-Score Charts** display the age and gender percentiles for the patient’s cohort per-vessel. The point shown on each illustrates where the patient’s FAI-Score sits within that cohort.
- 2 **FAI-Score and percentile** The per-vessel FAI-Score and percentile value.


A paper copy of this eIFU may be requested from the manufacturer at no additional cost. A paper copy will be provided within 7 days of request.

Device: CaRI-Heart 2.6
 Reference: 1964
 Copyright © 2024
 Caristo Diagnostics Ltd
 Rx Only UK CA CE
 0086 2797

 **Manufacturer**
 Caristo Diagnostics Ltd.
 New Barclay House
 234 Botley Road
 Oxford, OX2 0HP
 United Kingdom

 **EC Representative**
 EMERGO Europe
 Prinsessegracht 20
 The Hague
 2514 AP
 The Netherlands

Description of CaRI-Heart additional quantitative plaque reporting



The following plaque and stenosis information are provided for each measured coronary artery:

- | | |
|---|--|
| 1 Stenosis and Remodelling index | Are available for each plaque measured on the vessel. If stenosis is more non-zero or the remodelling index is greater than one. |
| 2 Overlay for each plaque region | Plaque regions demarcated by vertical light blue transparent regions with vertical lines indicating the start and end of each region. |
| 3 Straightened CPR visualization | Colour overlays are used to show the segmentations of different anatomical structures as shown in the key. |
| 4 Cross-sectional area chart | Chart displaying the area of the lumen and plaque found along the vessel from proximal to distal coloured according to the key. |
| 5 Quantitative measures | Calcified plaque (CP) volume, Low density non-calcified plaque (LDNCP) volume, Non-calcified plaque (NCP) volume (LDNCP + fibrous), Total Plaque volume (CP + NCP). Plaque Burden, Maximum Stenosis, and maximum remodelling index (described below) |

Stenosis	A quantitative measure of the maximum narrowing of the lumen due to atherosclerosis
Remodelling index	A measure of change in the vessel diameter due to plaques within the vessel wall
Plaque composition	The total volume of CP (calcified plaque), NCP (non-calcified or fibrous plaque) and LD-NCP (low-density non-calcified or fatty plaque).
Total Plaque volume	The total amount of plaque found within the measured region of the vessel
Plaque Burden	The percentage of the aggregate volume for sections of vessel containing plaque over the aggregate volume of plaque within those sections

A paper copy of this eIFU may be requested from the manufacturer at no additional cost. A paper copy will be provided within 7 days of request.

Device: CaRI-Heart 2.6
Reference: 1964
Copyright © 2024
Caristo Diagnostics Ltd








Manufacturer
Caristo Diagnostics Ltd.
New Barclay House
234 Botley Road
Oxford, OX2 0HP
United Kingdom





EC Representative
EMERGO Europe
Prinsessegracht 20
The Hague
2514 AP
The Netherlands

Warnings and Cautions

-  **CAUTION:** CaRI-Heart reports should not be used as a primary means of diagnosis.
-  **CAUTION:** CaRI-Heart reports are not a substitute for standard CCTA reports and do not contain incidental findings.
-  **CAUTION:** CaRI-Heart reports should be interpreted by a healthcare professional who retains the ultimate responsibility for making the pertinent diagnosis based on their standard practice.
-  **CAUTION:** CaRI-Heart reports are not intended to be used to guide revascularization strategy.
-  **CAUTION:** Timeframes for analysis results provision are contractually defined and are subject to delay. CaRI-Heart reports should not be requested for patients with unstable coronary syndromes or in patients where urgent and timely workup and evaluation is critical.

Notices

-  **NOTICE:** If a serious incident occurs in relation to the use of reports produced by the device, the competent authorities of the Member State and the Manufacturer shall be notified.
-  **NOTICE:** CaRI-Heart 2.6 uses an updated reference cohort for calculating FAI-Score percentiles, which may impact comparisons with previous versions of the device.

A paper copy of this eIFU may be requested from the manufacturer at no additional cost. A paper copy will be provided within 7 days of request.

Device: CaRI-Heart 2.6
Reference: 1964
Copyright © 2024
Caristo Diagnostics Ltd



Manufacturer
Caristo Diagnostics Ltd.
New Barclay House
234 Botley Road
Oxford, OX2 0HP
United Kingdom



EC Representative
EMERGO Europe
Prinsessegracht 20
The Hague
2514 AP
The Netherlands

Performance Characteristics

Reports from CaRI-Heart are not intended to provide a diagnosis and are intended only to be used as an additional clinical data point as part of a wider diagnostic process. The software and/or its methodologies have been validated through a variety of studies which have been widely published. A short sampling of the published data is as follows:

1. Kenneth Chan*, Elizabeth Wahome*, Apostolos Tsiachristas, Alexios S Antonopoulos, Parijat Patel, Maria Lyasheva, et al.: Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study. www.thelancet.com. *Lancet* 2024; [https://doi.org/10.1016/S0140-6736\(24\)00596-8](https://doi.org/10.1016/S0140-6736(24)00596-8)
2. Oikonomou EK, Antonopoulos AS, Schottlander D, et al. Standardized measurement of coronary inflammation using cardiovascular computed tomography: integration in clinical care as a prognostic medical device. *Cardiovasc Res* 2021; 117: 2677–90
3. Oikonomou EK, Marwan M, Desai MY, et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. *Lancet* 2018;392(10151):929-939
4. Antoniadou C, Shirodaria C. Detecting Coronary Inflammation With Perivascular Fat Attenuation Imaging: Making Sense From Perivascular Attenuation Maps. *JACC Cardiovasc Imaging* 2019;12(10):2011-2014
5. Antonopoulos AS, Sanna F, Sabharwal N, et al. Detecting human coronary inflammation by imaging perivascular fat. *Sci Transl Med* 2017;9(398).

A paper copy of this eIFU may be requested from the manufacturer at no additional cost. A paper copy will be provided within 7 days of request.

Device: CaRI-Heart 2.6
Reference: 1964
Copyright © 2024
Caristo Diagnostics Ltd



Manufacturer
Caristo Diagnostics Ltd.
New Barclay House
234 Botley Road
Oxford, OX2 0HP
United Kingdom



EC Representative
EMERGO Europe
Prinsessegracht 20
The Hague
2514 AP
The Netherlands